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TSiscussion
r Michael S. Mulligan (Seattle, Wash). This work adds to the
iterature underscoring the point that pumpless atrioventricular
upport of gas exchange has a place in the care of the critically ill.
O2 removal and O2 transfer are physiologies that can be uncou-
led and supported independently. I have several questions. The
ost consistent benefit demonstrated in the experience with the
ffinity and NovaLung devices relates to improved outcomes with
O2 removal in patients with ARDS. Entirely adequate rates of
O2 removal are achievable with device flows as low as 800 to
000 mL or 10% to 15% of CO. Therefore why is it necessary or
esirable to divert 30% to the CO through the device?
The oxygen transfer rate across this device seems high. One
ould assume that to achieve that, the arterial blood inflow must
e desaturated in the range of 65% or so. However, the low-
requency positive-pressure ventilation that you used and not ap-
eic ventilation, in fact, is highly effective at maintaining oxygen-
tion, as per the work of Kolobo. One would expect saturations in
hat paradigm in the range of 85% to 95%. Can you explain how
uch high levels of O2 transfer were achieved across this device?
f flows adequate for CO2 removal are attainable with small
ercutaneous cannulae, what is the real advantage to axillary
rterial dissection and potential grafting in what is likely to be a
ritically ill and nonambulatory population? Finally, the duration
f 4 hours on the device might not reflect a clinically useful
nterval. Similarly, comparing bronchoalveolar lavage cytokine
ontent from animals that had direct versus graft cannulation does
ot assess the inflammatory response attributable to pumpless
upport of gas exchange itself. Do you have any data from animals
efore and after the institution of support, allowing each animal to
erve as its own control? Thank you for sending me the manuscript
nd for continuing to help advance this important field.
Dr Macchiarini. As senior author, I take the privilege to
nswer the questions. Thank you for the questions. Thirty percent
f the CO is the normal range of the output that you might power
hrough the iLA when you put it on the femoral vessels, and this
as been used in almost more than 1000 patients thus far. There-
ore what we decided is to have an alternative, to in fact have less
O through the iLA and, as a matter of fact, through the graft
nterposition. We were able to flow only 10% of the CO, which
as approximately 1.2 L/min.
I cannot remember all the questions, but the last one was why
e chose this limited time of investigation. First of all, there are
rticles suggesting that 4 hours is enough at the given tidal volume
f 10 to 12 mL/kg to induce a lung injury, and therefore we used
The Journal of Thoracichat time frame. Thereafter, the second 4 hours of observation time
as simply because there is clinical evidence that the lung cyto-
ine response induced in patients with ARDS can be reversed
ithin 3 days, and probably you, better than I, know that in an
nimal setting this time corresponds to the 3 days in the clinical
ssue.
I cannot remember the other questions.
Dr Joseph B. Zwischenberger (Galveston, Tex). There are a
ouple of key points that the discussant brought up that still need
o be addressed. First of all, arteriovenous CO2 gas exchange has
een existent for about 10 to 15 years, and many of us have been
orking on this, and, as you alluded to, there is more than a
000-patient experience in Europe with the NovaLung. However,
here are 2 camps. One camp is the high-flow camp that wants to
et 20% to 30% of CO and access the femoral vessels with a large
annula (18F to 20F), and they have about a 25% complication rate
ith vascular access. Then there is the low-flow camp, to which I
elong, that goes for about 10% to 15% of CO and can use a 12F
o 14F cannula in which the complication rate is less than 5%. If
ou use the low-flow strategy, you can accomplish total CO2
emoval, but you do not contribute significantly to oxygenation
nd therefore rely on the native lungs. The key question in this
resentation is why do you report such large O2 transfer numbers,
nd why do you think such large flows are necessary, especially in
n animal that has normal native lungs and can accomplish oxy-
enation without difficulty?
Dr Macchiarini. Thank you, Joe.
The issue with the cannula, and you know better than I, is not
he volume. It is the resistance that they have. Therefore we might
alk about that in a later session. However, the O2 transfer that we
ad is probably because, at odds with your studies, we use an FIO2
f 1 and not lower because we did not want to have 2 different
arameters change in the same study, and this might explain why
e had more. Therefore because oxygenation was done through
he native lungs and not through the oxygenator, I think this could
robably explain this, keeping the FIO2 at 100% at the second
hase, the high oxygen transfer.
Dr Mulligan. Are you saying that your O2 transfer was attrib-
table to the native lung and not the device? That was not clear in
he manuscript. Therefore that is what you are saying, that you
upported CO2 scrubbing and O2 transfer independently, one with
he device and one with the native lung with low-frequency
ositive-pressure ventilation? Is that correct?Dr Macchiarini. Exactly.
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